Back to top

Video Blog

Today’s video takes a super quick look at shares of Monsanto (MON - Analyst Report) heading into their earnings release. The company doesn’t exactly have a great track record when it comes to earnings, as it has missed estimates in three of the last four quarters, including both of the last two.

Earnings estimates have also been sluggish for the stock, as the consensus estimate has been sliding over the past few months, and is back down to 2014 levels. However, the stock has moved out of Zacks Rank sell territory, and it is at least a hold now. Additionally, the company is in a great industry which is currently ranked in the top 10% overall so at least the overall space is promising, giving a very mixed picture overall.

MONSANTO CO-NEW Price, Consensus and EPS Surprise

MONSANTO CO-NEW Price, Consensus and EPS Surprise | MONSANTO CO-NEW Quote

But no matter how you feel about this name, it could be a company to avoid in the near term. Buyout rumors look likely to dominate the stock, and could override any news on the earnings front, no matter if it is another miss or a beat. The company received an offer from Bayer at about $128/share, but the stock is stuck in the low $100s thanks to antitrust concerns. As we learn more about this, it will likely override any news on the earnings front, at least over the long term.

Monsanto reports before the bell on October 5th and we are looking for a loss of two cents per share from the company. Make sure to watch the video for a quick guide to MON heading into the release, but if you want some insights on how to trade stocks ahead of earnings reports, check out our podcast on the topic below:

The Best & Worst of Zacks

Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +26% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 11X worse than the market. See these critical buys and sells free >>

In-Depth Zacks Research for the Tickers Above